Contract wins with existing client

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has been selected to proceed with three follow on projects to the stable Cell Line Development project (the "CLD Project") announced on 27 February 2025. The original contract and the follow-on contracts (the "New Contracts") all operate under a collaborative research and development agreement (the "Agreement") with a US based biotechnology company (the "Client").

Work in relation to the CLD Project under the original contract was expected to last between six to nine months. The New Contracts build on the successful progress to date with the original project, extending its scope and establishing a further new engineering project for the Client. The New Contracts are valued at c. $460,000, of which a minimum of $400,000 is expected to be recognised in the current financial year ending 31 March 2026.

Adrian Kinkaid, CEO of Fusion, said: "We are delighted to extend our agreement with this significant client and to add a further earlier stage project to the pipeline of work we are undertaking with them. We look forward to continuing to work with our Client to bring better antibodies to the clinic more rapidly. These New Contracts and the CLD Project highlights the strong reputation that Fusion has for delivering high quality therapeutic antibodies and their associated cell lines: a part of our offering with excellent scope for growth."